JNawfal R Hussein.
Department of Biomedical Sciences, The College of Medicine, University of Zakho, Kurdistan Region of Iraq.
Correspondence to: Nawfal
R Hussein. Room 94, Main building, University campus, The department of
biomedical sciences, The College of Medicine, University of Zakho,
Kurdistan Region of Iraq. E-mail:
Nawfal.hussein@yahoo.com
Published: May 1, 2022
Received: March 15, 2022
Accepted: April 5, 2022
Mediterr J Hematol Infect Dis 2022, 14(1): e2022035 DOI
10.4084/MJHID.2022.035
This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0),
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
|
To the editor
We
learned with pleasure that The Mediterranean Journal of Hematology and
Infectious Diseases had hit a new milestone by obtaining an impact
factor of 2.576. We want to congratulate you on this achievement. From
our point of view, in a country with poor resources and enthusiastic
researchers, the MJHID was a shelter for our papers. This Journal
provides three advantages for us. Firstly, English language weakness
does not influence the decision, and secondly, it provides a good guide
to the researcher to build a good quality project. Thirdly, the
communication with the Editor is straightforward without obstacles.
Utilizing such advantages, we could have published good papers in the
MJHID, gaining readers’ attention and recording good citations.[1-5]
It is believed that the advantages the MJHID provided to authors have
played a role in hitting such a milestone. The new Journal’s
achievement should not change its standards to continue encouraging us
all the researchers of low-income countries. Therefore, we believe that
hitting a new milestone should drive you to increase the help to
researchers in the low-income research setting and where the research
resources are sparse. We suggest the Journal establish a mentoring
committee to help such researchers meet international standards and
make necessary amendments to the projects rather than rejecting the
papers in the first screening and/or revision round. Finally, in a
world full of challenges for researchers who work in an environment
that does not appreciate and support research, we hope to support and
provide a platform that makes our voice heard.
References
- Hussein NR. The efficacy and safety of
sofosbuvir-containing regimen in the treatment of HCV infection in
patients with haemoglobinopathy. Mediterranean Journal of Hematology
and Infectious Diseases. 2017;9(1) :e2017005. https://doi.org/10.4084/mjhid.2017.005 PMid:28105296 PMCid:PMC5224801
- Hussein
NR, Naqid IA, Saleem ZSM. A retrospective descriptive study
characterizing coronavirus disease epidemiology among people in the
Kurdistan Region, Iraq. Mediterranean Journal of Hematology and
Infectious Diseases. 2020;12(1):e2020061. https://doi.org/10.4084/mjhid.2020.061 PMid:32952972 PMCid:PMC7485477
- Hussein
NR, Naqid IA, Salih HM. The efficacy and safety of intralesional sodium
stibogluconate for the treatment of cutaneous Leishmaniasis in children
under the age of two years. Mediterranean Journal of Hematology and Infectious Diseases. 2020;12(1) :e2020027. https://doi.org/10.4084/mjhid.2020.027 PMid:32395216 PMCid:PMC7202348
- Hussein
NR, Rashad BH, Almizori LA, Yousif SS, Sadeeq AT, Abdulkareem YR, et
al. The risk of SARS-CoV-2 reinfection in Duhok city, Kurdistan region
of Iraq. Mediterranean Journal of Hematology and Infectious Diseases.
2021;13(1):e2021035. https://doi.org/10.4084/MJHID.2021.035 PMid:34007423 PMCid:PMC8114888
- Hussein
NR, Saleema ZS, Abd QH. Direct acting antiviral treatment for patients
with end-stage kidney disease with acute HCV infection. Mediterranean
Journal of Hematology and Infectious Diseases. 2019;11(1):e2019034. https://doi.org/10.4084/mjhid.2019.034 PMid:31205638 PMCid:PMC6548205
[TOP]